Neuroscience Research Institute
Clinical Trials
: BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease (Brainshuttle AD)
This study is currently enrolling.
Trontinemab is an experimental drug that is being developed for the possible treatment of AD. Trontinemab combines an anti-amyloid antibody with a brain shuttle module which helps to deliver the antibody to the brain. It works ...
A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE
This study is currently enrolling.
The purpose of this study is to investigate what happens to RO7486967 once it is in the body, what RO7486967 does to the body, and to compare the effects (good or bad) of RO7486967 versus placebo on the inflammation in the brai ...
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
This study is currently enrolling.
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, the aim of this study is to find out if you e ...
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is currently enrolling.
The purpose of this study is to see if batoclimab is safe and helps people with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disorder. Batoclimab is also known as IMVT-1401 (and was previously referre ...
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease
This study is currently enrolling.
You may be eligible to take part in the study because you have Parkinson’s Disease (PD). Only people who have been diagnosed with PD in the past 2 years and who are within the ages of 30 to 80 years can take part in the study. ...
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
This study is currently enrolling.
The purpose of this study is to see if an experimental drug, called Milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient isc ...
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
This study is currently enrolling.
The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer MS relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known ...
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CARISBAMATE (YKP509) AS ADJUNCTIVE TREATMENT FOR SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN CHILDREN AND ADULTS,
WITH OPTIONALOPEN-LABEL EXTENSION
WITH OPTIONALOPEN-LABEL EXTENSION
This study is currently enrolling.
Participants will be asked to join this study because they have Lennox-Gastaut Syndrome (LGS), a rare type of epilepsy that results in abnormal brain activity and seizures. It usually starts at an early age and causes seizures ...
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Months
At least 6 Months
This study is currently enrolling.
The purpose of the study is to evaluate daily oral doses of the study drug called venglustat compared to placebo: what is the effectiveness (how well it works) on symptoms of the Fabry disease, mainly neuropathic pain and abdom ...